An Overview of Minimal Residual Disease Market Growth and Trends

After treatment, the few cancer cells still present in the body are called minimal residual disease (MRD). The surviving cells may be so few that they don't cause visible symptoms or signs. They are typically undetectable by more common methods like looking at cells under a microscope or testing the blood for abnormal serum proteins. A positive MRD test result indicates that there is still illness present. Negative results indicate that no residual illness was found.

Moreover, MRD testing is also helpful in clinical trials for the latest medicines. It can demonstrate how well the treatment cures cancer without waiting months to see if it returns. This results in overall minimal residual disease market growth. The global minimal residual disease market was valued at USD 1,973.35 million in 2022 and is expected to grow to USD 7,131.61 million at a CAGR of 13.7% during the forecast period.

Major Growth Driving Factors

• Increased cancer occurrences: During the forecast period, cancer incidences have significantly increased and are anticipated to enormously impact the market growth for therapies for low residual sickness. It is expected that during the forecast period, cancer patients receiving cancer treatments will support the expansion of the market for minimal residual disorders.
• Technological Developments: The minimal residual disease market size is being driven by the creation and application of NGS technologies, data integration, technological advancements in cloud computing, and the accessibility of a technologically advanced framework for healthcare research. Along with this, the minimal residual disease market growth is primarily driven by the growth of genome mapping programs and the improved regulatory and restitution environment for NGS-based diagnostic tests.

Top Report Findings:

• The market is growing due to increased cancer patients and R&D expenditure. Another element propelling this market is the expanding use of next-generation sequencing (NGS) technologies.
• The minimal residual disease market segmentation is based on detection target, end-user, test technique, and region.

Minimal Residual Disease Market Trends

• Treatment Accuracy: Due to the challenges of using FISH, PCR, and flow cytometry to count 1 in every 100,000 cells, it is anticipated that the patient's attention will move towards minimum residual disease. Adopting cutting-edge technology benefits patients by increasing the accuracy of their treatments. These elements could have an impact on the market as a whole

Segment Review

Leukemia Dominates the Market

Since one American is diagnosed with leukemia every three minutes, it will rule the market. For example, the American Cancer Society evaluates that there will be roughly 20,050 new cases of acute myeloid leukemia, 60,650 new cases of leukemia overall, and 24,000 new leukemia-related deaths in 2022. Annual new cases of leukemia were 14.1 per 100,000 men and women. The yearly death rate for both men and women was 6.0 per 100,000.

Healthcare Organizations Hold the Market Share

Hospitals and specialty clinics accounted for the highest minimal residual disease market share. Hospitals have staff members that can help patients choose appropriate MRD tests, which is the main factor driving the market. The target illness is becoming more common; numerous testing options are available, and new tests are being developed for more precise and effective patient screening.

Geographical Analysis

North America: Minimal residual disease market in North America is anticipated to expand significantly during the projection period due to increasing healthcare affordability in the United States. North America dominates the industry for minimal residual illness. The U.S. and Canada are North America's two main markets for cancer screening due to the high patient and physician awareness of the benefits of screening.

Recent Developments

• The Digital LightCycler device, which Roche introduced in August 2022, is the company's first digital polymerase chain reaction (PCR) device that can correctly measure tiny amounts of a particular RNA or DNA and is used to identify diseases.
• Guardant launched the Guardant Reveal Liquid Biopsy diagnostic in February 2021 as a recurrence surveillance and residual illness diagnostic.

Frequently Asked Questions

• What will the minimal residual disease market be worth during the forecast period?
• Who are the key market players?
• What are the market segments of the minimal residual disease market?
• What are the major growth drivers of the market?
• Wich region contributes significantly towards the market?
• What will be the expected CAGR during the forecast period?

By Detection Target

• Lymphoma
• Leukemia
• Solid Tumors
• Others

By Test Technique

• Flow Cytometry
• Polymerase Chain Reaction (PCR)
• Next Generation Sequencing (NGS)
• Others

By End User

• Hospitals and Specialty Clinics
• Laboratory Centres

By Region

• North America (U.S., Canada)
• Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
• Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
• Latin America (Brazil, Mexico, Argentina)
• Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

Deep-dive Insights on Minimal Residual Disease Market by Polaris Market Research: https://www.polarismarketresearch.com/industry-analysis/minimal-residual-disease-market/request-for-sample